Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.

Many recombinant poxviral vaccines are currently in clinical trials for cancer and infectious diseases. However, these agents have failed to generate T cell responses specific for recombinant gene products at levels comparable with T cell responses associated with natural viral infections. The recen...

Bibliografiset tiedot
Päätekijät:	Smith, C, Mirza, F, Pasquetto, V, Tscharke, D, Palmowski, M, Dunbar, P, Sette, A, Harris, A, Cerundolo, V
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	2005

Samankaltaisia teoksia

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.
Tekijä: Smith, C, et al.
Julkaistu: (2005)

Immunodomination during peripheral vaccinia virus infection.
Tekijä: Leon C W Lin, et al.
Julkaistu: (2013-01-01)

Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
Tekijä: Sharpe, S, et al.
Julkaistu: (2003)

Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein.
Tekijä: Gileadi, U, et al.
Julkaistu: (1999)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
Tekijä: Caroline Staib, et al.
Julkaistu: (2003-04-01)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
Tekijä: Dorrell, L, et al.
Julkaistu: (2000)

Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
Tekijä: Valmori, D, et al.
Julkaistu: (2000)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
Tekijä: Alharbi, N
Julkaistu: (2014)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
Tekijä: McConkey, S, et al.
Julkaistu: (2003)

Clinical development of Modified Vaccinia virus Ankara vaccines.
Tekijä: Gilbert, S
Julkaistu: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
Tekijä: Gilbert, S
Julkaistu: (2013)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
Tekijä: Rosario, M, et al.
Julkaistu: (2010)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
Tekijä: Hanke, T, et al.
Julkaistu: (1998)

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.
Tekijä: Allen, T, et al.
Julkaistu: (2000)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
Tekijä: Matthew G Cottingham, et al.
Julkaistu: (2008-02-01)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
Tekijä: Behboudi, S, et al.
Julkaistu: (2004)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
Tekijä: Cottingham, M, et al.
Julkaistu: (2008)

Selection of Vaccinia Virus Recombinants Using CRISPR/Cas9
Tekijä: Anjali Gowripalan, et al.
Julkaistu: (2021-12-01)

Poxviral Ankyrin Proteins
Tekijä: Michael H. Herbert, et al.
Julkaistu: (2015-02-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA).
Tekijä: Matthew G. Cottingham, et al.
Julkaistu: (2011-01-01)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
Tekijä: Ansar A Pathan, et al.
Julkaistu: (2007-10-01)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
Tekijä: C. Staib, et al.
Julkaistu: (2000-06-01)

Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity.
Tekijä: Sharpe, S, et al.
Julkaistu: (2001)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
Tekijä: Olga Vladimirovna Orlova, et al.
Julkaistu: (2022-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
Tekijä: Volker Sandig, et al.
Julkaistu: (2013-11-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
Julkaistu: (2011-01-01)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
Tekijä: Pathan, A, et al.
Julkaistu: (2007)

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials.
Tekijä: Ansar A. Pathan, et al.
Julkaistu: (2011-01-01)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
Tekijä: Pathan, A, et al.
Julkaistu: (2007)

Diseño y construcción de vectores de transferencia para la obtención de virus vaccinia Ankara modificado (MVA) recombinantes Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)
Tekijä: M. F. Ferrer, et al.
Julkaistu: (2007-09-01)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
Tekijä: Moorthy, V, et al.
Julkaistu: (2003)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
Tekijä: Flavia Chiuppesi, et al.
Julkaistu: (2024-02-01)

Methods of treating Poxviral Infections
Tekijä: Ramstedt, U, et al.
Julkaistu: (2011)

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
Tekijä: McShane, H, et al.
Julkaistu: (2004)

Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).
Tekijä: Rachael Chiam, et al.
Julkaistu: (2009-06-01)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
Tekijä: Mingwang Shen, et al.
Julkaistu: (2024-10-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
Tekijä: Kaïdre Bendjama, et al.
Julkaistu: (2017-09-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
Tekijä: Malachy I. Okeke, et al.
Julkaistu: (2017-10-01)

Nodular Dermatitis: Emergence of Novel Poxviral Infection in Russia
Tekijä: S. V. Borisevich, et al.
Julkaistu: (2018-04-01)

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
Tekijä: Webster, D, et al.
Julkaistu: (2005)